

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and ONL Therapeutics, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professor David Zacks is an employee of the University of Michigan (“University”), and a partial owner of ONL Therapeutics, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

David Zacks, MD, PhD, a Professor in the Department of Ophthalmology and Visual Sciences, is the partial owner of a for-profit company called ONL Therapeutics, Inc. (the “Company”). The Company wishes to fund a project entitled “Testing Neuroprotective effect of ONL-1204 Ocular Formulation Dose Response in Mouse Retinal Ischemia Injury Model” (ORSP# 18-PAF03755) in the Department of Ophthalmology and Visual Sciences under the direction of Dr. Steven Abcouwer. The purpose of this project is to test the efficacy of intravitreal injections of 3 dosages of the Fas inhibiting peptide ONL1204 on the neurodegenerative (apoptotic) response to retinal ischemia-reperfusion (IR) injury in mice.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed \$150,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Abcouwer to use his expertise and University laboratory, as well as other University resources, to test the efficacy of intravitreal injections of dosages of the Fas inhibiting peptide ONL1204 on the neurodegenerative (apoptotic) response to retinal ischemia-reperfusion (IR) injury in mice.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with ONL Therapeutics, Inc.

Respectfully submitted,



S. Jack Hu  
Vice President for Research

February 2018